{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.54","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1"},{"groupId":"OG001","value":"10.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"94"}],"units":"Participants"}],"description":"Will compare vaccine and placebo recipients. Will evaluate differences in the hazard of recurrence using Cox proportional hazards in the intention to treat population and the per protocol population.","groups":[{"description":"Patients receive recombinant human papillomavirus nonavalent vaccine IM at baseline, 2 months, and 6 months.\n\nLaboratory Biomarker Analysis: Correlative studies\n\nQuestionnaire Administration: Ancillary studies\n\nRecombinant Human Papillomavirus Nonavalent Vaccine: Given IM","id":"OG000","title":"Arm I (Recombinant Human Papillomavirus Nonavalent Vaccine)"},{"description":"Patients receive placebo IM at baseline, 2 months, and 6 months.\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPlacebo Administration: Given IM\n\nQuestionnaire Administration: Ancillary studies","id":"OG001","title":"Arm II (Placebo)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to month 36","title":"Time to Recurrence of Anogenital High Grade Squamous Intraepithelial Lesion (HSIL)","type":"SECONDARY","unitOfMeasure":"Recurrent events per 100 person-years"}